Mark D. Schuman

Carlson Caspers represented Teva and Glenmark in this Paragraph IV Hatch-Waxman case concerning the drug saxagliptin (Onglyza®), which challenged the infringement of a listed Orange Book patent. We successfully negotiated with AstraZeneca for the early dismissal of both Teva and Glenmark based on their non-infringement of the asserted patent.